These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 3414260)
1. [Middle-molecule spectrum of the blood serum in patients with a continuously progressive paranoid form of schizophrenia undergoing treatment]. Turianitsa IM; Mishanich II; Rostoka LM Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(5):109-11. PubMed ID: 3414260 [TBL] [Abstract][Full Text] [Related]
2. [Free amino acids and the total middle molecule fraction of the blood serum in patients with continuously progressive paranoid schizophrenia undergoing treatment]. Mishanich II; Turianitsa IM; Pashchenko AE; Rostoka LM; Iliushina SN Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(1):107-10. PubMed ID: 3364087 [TBL] [Abstract][Full Text] [Related]
3. [Correlation of the results of neurotensin therapy and plasma levels in paranoid schizophrenia]. Zych F; Zgirski L; Krowicki Z; Urban S; Sadowska-Krowicka H Psychiatr Pol; 1990; 24(5):23-7. PubMed ID: 2131473 [TBL] [Abstract][Full Text] [Related]
4. [Use of triphthazine in the treatment of mentae disorders]. Gurowitsch IJ; Awruzki GJ Psychiatr Neurol Med Psychol (Leipz); 1975 May; 27(5):284-91. PubMed ID: 812131 [TBL] [Abstract][Full Text] [Related]
6. Chlorpromazine in the blood of schizophrenics. Sikora J; Krulík R; Král J; Novotný J Act Nerv Super (Praha); 1978 Dec; 20(4):278-80. PubMed ID: 735734 [No Abstract] [Full Text] [Related]
7. [Plasma levels of various catecholamines in schizophrenic patients during treatment with chlorpromazine]. Olajossy M; Solski J; Ksiazek A Psychiatr Pol; 1987; 21(3):246-50. PubMed ID: 3423147 [No Abstract] [Full Text] [Related]
8. [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]. Lü LX; Guo SQ; Chen W; Li Q; Cheng J; Guo JH Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1251-4. PubMed ID: 15567770 [TBL] [Abstract][Full Text] [Related]
9. Acute paranoid schizophrenia. (Treatment with chlorpromazine, trifluoperazine and placebo). Reardon JD; Abrams S Dis Nerv Syst; 1966 Apr; 27(4):265-70. PubMed ID: 5936140 [No Abstract] [Full Text] [Related]
10. [Comparative study of clothiapine and trifluoperazine in acute episodes of paranoid schizophrenia]. Perales JA; Garcia A; Infantes V; Valle G Acta Psiquiatr Psicol Am Lat; 1974 Jun; 20(3):207-13. PubMed ID: 4153184 [No Abstract] [Full Text] [Related]
11. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. Tuason VB; Escobar JI; Garvey M; Schiele B J Clin Psychiatry; 1984 Apr; 45(4):158-63. PubMed ID: 6370967 [TBL] [Abstract][Full Text] [Related]
12. Elevated levels of clozapine in serum after addition of fluvoxamine. Hiemke C; Weigmann H; Härtter S; Dahmen N; Wetzel H; Müller H J Clin Psychopharmacol; 1994 Aug; 14(4):279-81. PubMed ID: 7962687 [No Abstract] [Full Text] [Related]
13. [Adaptation to neuroleptic preparations and several ways of combatting it (experimental study)]. Neduva AA; Zharkovskiĭ AM; Matvienko OA; Beliakov AV Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(8):1226-31. PubMed ID: 4050238 [TBL] [Abstract][Full Text] [Related]
14. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients. Segal M; Avital A; Berstein S; Derevenski A; Sandbank S; Weizman A Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):378-82. PubMed ID: 17110010 [TBL] [Abstract][Full Text] [Related]
15. [Long-term moditen-depot treatment of schizophrenic patients at a psychoneurology dispensary]. Abramova LI; Gushanskiĭ EL Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(3):419-24. PubMed ID: 3705854 [TBL] [Abstract][Full Text] [Related]
16. [A therapeutic pathomorphosis of schizophrenia proceeding with paranoid disorders]. Ozola MIa Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(4):600-5. PubMed ID: 5497116 [No Abstract] [Full Text] [Related]
17. [Relationship between plasma thioridazine level and the symptoms of paranoid schizophrenia]. Afeltowicz Z Psychiatr Pol; 1979; 13(3):223-33. PubMed ID: 472063 [No Abstract] [Full Text] [Related]
18. [Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)]. Avrutskiĭ GIa; Allikmets LKh; Neduva AA; Zharkovskiĭ AM; Beliakov AV Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1213-20. PubMed ID: 6495946 [TBL] [Abstract][Full Text] [Related]
19. [Place of clinical and pharmacokinetic parameters in prognosing the effectiveness of schizophrenic therapy]. Panteleeva GP; Minsker EI; Tsirkin SIu; Beliaev BS; Lukanina SK Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):748-54. PubMed ID: 7415697 [TBL] [Abstract][Full Text] [Related]
20. [The evaluation of the efficacy of efferent therapy in patients with acute and chronic kidney failure by the spectrum of blood middle-molecule fractions]. Kon'kova TA; Chudnovskaia MV; Golovanov SA Urol Nefrol (Mosk); 1994; (4):35-7. PubMed ID: 7985299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]